Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

This pharma stock has made strong gains over the past 12 months thanks to its strong earnings. Now it is testing a fresh buy ...

Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy ...